Asymchem Laboratories (Tianjin) Co., Ltd.

XSEC:002821 Stock Report

Market Cap: CN¥26.2b

Asymchem Laboratories (Tianjin) Past Earnings Performance

Past criteria checks 2/6

Asymchem Laboratories (Tianjin) has been growing earnings at an average annual rate of 38.8%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 32.5% per year. Asymchem Laboratories (Tianjin)'s return on equity is 10.8%, and it has net margins of 27.5%.

Key information

38.8%

Earnings growth rate

36.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate32.5%
Return on equity10.8%
Net Margin27.5%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Asymchem Laboratories (Tianjin) makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:002821 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 246,9761,9201,019715
31 Dec 237,8252,269991708
30 Sep 238,8042,7911,042780
30 Jun 239,8393,248957769
31 Mar 2310,4453,433976740
01 Jan 2310,2553,302980709
30 Sep 229,5083,094853572
30 Jun 227,9182,382801487
31 Mar 225,9151,413672435
31 Dec 214,6321,068594387
30 Sep 213,977908522346
30 Jun 213,626830471314
31 Mar 213,438766468288
31 Dec 203,137719427259
30 Sep 202,800694392228
30 Jun 202,633640380223
31 Mar 202,459570360210
31 Dec 192,460554360193
30 Sep 192,372534347188
30 Jun 192,170501343179
31 Mar 191,948457308161
31 Dec 181,835428284155
30 Sep 181,732401246130
30 Jun 181,629373170152
31 Mar 181,497356184128
31 Dec 171,42334120197
30 Sep 171,21326523769
30 Jun 171,1842892850
31 Mar 171,2072692760
31 Dec 161,1032532570
30 Sep 161,0972602200
31 Dec 158311542030
31 Dec 147161021730
31 Dec 13543751360

Quality Earnings: 002821 has high quality earnings.

Growing Profit Margin: 002821's current net profit margins (27.5%) are lower than last year (32.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002821's earnings have grown significantly by 38.8% per year over the past 5 years.

Accelerating Growth: 002821's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002821 had negative earnings growth (-44.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 002821's Return on Equity (10.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.